China Releases Revised Draft Amendment to Drug Registration Regulation

Global Life Sciences: China Update

On February 19, 2014, China’s State Council Legislative Affairs Office released a revised draft amendment to the Drug Registration Regulation (DRR). Public comments are due by March 23, 2014. The revised draft updates the draft DRR amendment that CFDA published for comment in November 2013 (see China CFDA Amending its Drug Registration Regulation).

Most noteworthy in this revised draft amendment is the retention of part of old Article 19 of the DRR, which CFDA had earlier proposed to delete. Original Article 19 requires CFDA to (i) accept generic filings two years before expiration of the relevant patents of the innovative drug, and (ii) issue market approvals to generic manufacturers only after the relevant patents expire. In the revised draft, the two-year window for generic filings is eliminated, permitting generic manufacturers to file applications and CFDA to accept and review such applications any time during the relevant patent terms.

A new requirement is also added to the revised Article 19, however, under which generic drug approvals issued by CFDA “will only become effective upon expiration of the relevant patents.” This is a significant development for the protection of patented drugs. If finalized, it would work in tandem with the China patent linkage system under which generic versions of a patented drug may not be manufactured in China until the relevant patents expire.

Given the potential impact of these changes on regulatory strategy and requirements in China, companies should carefully review the revised draft amendment to the DRR and submit comments by the March 23 deadline.

Contacts

For further information on this client updatee China Life Science Practice, please contact:

Chen Yang

+86.10.5905 5600

cyang@sidley.comLing Su

+86.21.2322.9327

ling.su@sidley.com

Related Practices

Sidley China Life Sciences Practice

Sidley Global Life Sciences Practice

To receive future copies of this and other Sidley updates via email, please sign up at www.sidley.com/subscribe.

Sidley Austin provides this information as a service to clients and other friends for educational purposes only. It should not be construed or relied on as legal advice or to create a lawyer-client relationship.

Attorney Advertising - For purposes of compliance with New York State Bar rules, our headquarters are Sidley Austin LLP, 787 Seventh Avenue, New York, NY 10019, 212.839.5300; One South Dearborn, Chicago, IL 60603, 312.853.7000; and 1501 K Street, N.W., Washington, D.C. 20005, 202.736.8000.